DaVita Inc. (NYSE:DVA) Given Average Rating of “Hold” by Brokerages

DaVita Inc. (NYSE:DVA) has been assigned a consensus recommendation of “Hold” from the five brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and one has issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $161.80.

A number of equities analysts have recently commented on the stock. UBS Group raised their price objective on shares of DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Truist Financial lifted their price target on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. Bank of America lifted their price target on shares of DaVita from $139.00 to $145.00 and gave the company an “underperform” rating in a report on Wednesday, August 7th. Finally, Barclays lifted their price target on shares of DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st.

Insiders Place Their Bets

In other DaVita news, CEO Javier Rodriguez sold 9,881 shares of the business’s stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $162.85, for a total value of $1,609,120.85. Following the completion of the transaction, the chief executive officer now directly owns 887,835 shares of the company’s stock, valued at approximately $144,583,929.75. The trade was a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 2.00% of the company’s stock.

Hedge Funds Weigh In On DaVita

Institutional investors have recently modified their holdings of the stock. Transcendent Capital Group LLC bought a new position in shares of DaVita in the third quarter worth about $25,000. Blue Trust Inc. raised its stake in shares of DaVita by 58.6% in the second quarter. Blue Trust Inc. now owns 211 shares of the company’s stock worth $29,000 after acquiring an additional 78 shares during the last quarter. Family Firm Inc. acquired a new stake in shares of DaVita during the 2nd quarter worth approximately $43,000. Versant Capital Management Inc grew its position in shares of DaVita by 90.6% during the 2nd quarter. Versant Capital Management Inc now owns 326 shares of the company’s stock worth $45,000 after buying an additional 155 shares during the period. Finally, Friedenthal Financial acquired a new stake in shares of DaVita during the 2nd quarter worth approximately $48,000. 90.12% of the stock is owned by institutional investors.

DaVita Price Performance

NYSE:DVA opened at $166.99 on Tuesday. The company has a 50-day moving average of $158.34 and a 200-day moving average of $148.65. The company has a market capitalization of $13.69 billion, a price-to-earnings ratio of 18.01, a PEG ratio of 0.93 and a beta of 0.89. DaVita has a 52 week low of $98.26 and a 52 week high of $169.12. The company has a debt-to-equity ratio of 15.78, a quick ratio of 1.33 and a current ratio of 1.37.

DaVita (NYSE:DVA) last released its quarterly earnings data on Tuesday, October 29th. The company reported $2.59 EPS for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). The business had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a return on equity of 88.18% and a net margin of 6.53%. DaVita’s revenue was up 4.6% on a year-over-year basis. During the same period in the previous year, the business posted $2.85 earnings per share. As a group, equities research analysts anticipate that DaVita will post 9.71 earnings per share for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.